ArticleNature biotechnology2026

Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma.

Shuo Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.